

# MAPS in the Media



## New Hope in Treating PTSD with Psychedelic Drugs

David Martin • Nov 14, 2021

CBS News airs an investigative report about treating PTSD with MDMA-assisted therapy on a new episode of CBS Sunday Morning. In a series of interviews with David Martin of CBS TV, former Marine Scott Ostrom speaks about participating in a MAPS-sponsored trial, MAPS Founder Rick Doblin, Ph.D., outlines the process of overcoming obstacles associated with psychedelic research, entrepreneur Bob Parsons of We Deal In Hope explains why he donates to MAPS, and PTSD expert Rachel Yehuda, Ph.D., highlights the promising results from MAPS' first Phase 3 trial.



Psychedelics, Consciousness Technologies, and the Future of Wellness

## Denver Launches the First Psychedelic Harm Reduction Training in the U.S.

Ali McGhee • Aug 19, 2021

"MAPS is spearheading the training" of psychedelic harm reduction for first responders in Denver, Colorado, where possession and personal use of psilocybin has been decriminalized since May 2019, "and, through philanthropic donations, is funding the training development through completion of the initial pilot phase," reports Ali McGhee of Lucid News.



## New Research Shows How Psychedelic Drug Can Help People with PTSD

Savannah Guthrie • Nov 5, 2021

The TODAY Show on NBC educates millions of people about psychedelic science by airing an interview with MAPS Founder Rick Doblin, Ph.D., and MDMA-assisted therapy study participants Andy Gold and SGT(R) Jonathan Lubecky. We are excited to see the results of MAPS-sponsored psychedelic research reaching the hearts and minds of large audiences as we continue to advocate for increased access to psychedelic-assisted therapy.



## Expert: MDMA for the Treatment of PTSD May Be FDA-Approved by the End of 2023

Alana Hippensteels • Oct 19, 2021

Pharmacy Times interviews Ismail Lourido Ali, J.D., of MAPS about MDMA-assisted therapy for PTSD, drug policy reform, and the impact of psychedelic science. "We're focusing primarily on PTSD as the indication for MDMA, but there are a number of investigator-initiated trials and other research about MDMA that has looked at a number of other indications," says Ali.

## Los Angeles Times

### Psychedelic Treatments Are Here, but Doctors Aren't Prepared

Jennifer Ho Lan Ouyang & Rick Doblin • Aug 29, 2021

The Los Angeles Times publishes a new op-ed co-authored by MAPS Founder Rick Doblin, Ph.D., and Stanford Psychedelic Science Group Co-Founder Jennifer Ouyang Altman, featuring commentary about recent shifts in public perception of psychedelics, the significant progress of psychedelic research, varying approaches to new drug policy initiatives, and the importance of psychedelic education. "The federal government has supported finding new effective psychiatric treatments. The FDA has designated MDMA-assisted and psilocybin-assisted therapy as breakthrough therapies, a status granted when preliminary clinical evidence indicates that a drug may demonstrate substantial improvement over available therapies."



## Michigan's Marijuana Tax Revenue Funds \$20M Studies on Medical Cannabis for Veterans With PTSD

Steve Neavling • Aug 11, 2021

Detroit Metro Times reports on the decision from Michigan's Marijuana Regulatory Agency (MRA) to award MAPS a \$12,979,050 grant for a Phase 2 clinical trial of self-titrated high-THC cannabis against placebo for treatment of PTSD among Veterans, funded by adult-use marijuana retail taxes in Michigan.

## HARVARD LAW TODAY

### The Obstacles to Decriminalizing Psychedelic Drugs Are Political, Not Legal, Say Experts

Brett Milano • Oct 13, 2021

Harvard Law Today covers the launch of the Project on Psychedelics Law and Regulation (POPLAR) at Harvard Law School's Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics. "We think it's going to require a decade of psychedelic clinics being rolled out, for people to hear about the positive experiences," says MAPS Founder and Executive Director Rick Doblin, Ph.D., in his keynote address. "We'll have licensed legalization, I think, in 2035."

## Les Echos

### Rick Doblin, L'homme Qui Drogue Pour Soigner (The Man Who Drugs to Cure)

Ana s Moutot • Sept 2, 2021

French financial newspaper Les Echos profiles MAPS Founder Rick Doblin, Ph.D., in an article about MAPS' 35-year history, the results from the first Phase 3 clinical trial of MDMA-assisted therapy for PTSD, and the future of psychedelic medicine.



### Psychedelics Are Getting Closer to Approval, but the Market May Not Be Ready

Amirah Al Idrus • Aug 17, 2021

FierceBiotech chronicles MAPS' ongoing road to potential FDA approval of MDMA-assisted therapy for the treatment of PTSD, highlighting the uncertainty facing the broader medical field as rigorous studies continue to demonstrate the efficacy of psychedelic-assisted therapies. Amy Emerson, Chief Executive Officer of MAPS Public Benefit Corporation (MAPS PBC), explains the unique regulatory factors that apply to the integration of psychedelics into mainstream medicine.

## FOCUS

### Trip-Therapie: Psychedelische Drogen in der Medizin

Matthias von Hein • Oct 4, 2021

FOCUS Online, a German media publication, interviews MAPS Founder Rick Doblin, Ph.D., about the current state of psychedelic research, highlighting MAPS' strategy for making MDMA-assisted therapy a legal prescription treatment option for PTSD around the world.

## verywell health

### Will We Turn to Psychedelics for Mental Health Treatment After the Pandemic?

Jennifer Chesak • Oct 26, 2021

Verywell Health explores the potential impact that psychedelics could have on healing trauma caused by the COVID-19 pandemic in an interview with MAPS Founder Rick Doblin, Ph.D. "Doblin projected that interest and use of psychedelics will grow over the next several years, with legalization likely happening around 2035, explains Jennifer Chesak of Verywell Health. "The psychedelic renaissance will continue to unfold in the post-pandemic world as research—and potentially FDA approval—helps fine-tune how the compounds should be used to treat the traumas left in the wake of COVID-19."

## BENZINGA

### Can MDMA Treat Traumatic Brain Injury? \$1.5 Million Are Being Committed to Finding Out

Natan-Ponienman • Sep 14, 2021

Benzinga reports that Wesana will provide an initial \$1.5 million engagement fee to explore the viability of collaborating with MAPS and MAPS PBC to accelerate research into MDMA-assisted therapy for traumatic brain injury (TBI). The engagement fee will be used by MAPS and MAPS PBC, in part, to finance the evaluation of legal, scientific, and operational elements of the proposed commercial relationship.